<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041129</url>
  </required_header>
  <id_info>
    <org_study_id>16-2399</org_study_id>
    <nct_id>NCT03041129</nct_id>
  </id_info>
  <brief_title>Post-Prandial Liver Glucose Metabolism in Polycystic Ovarian Syndrome (PCOS) and Understanding Standard of Care Medications</brief_title>
  <acronym>PLUM</acronym>
  <official_title>Post-Prandial Liver Glucose Metabolism in Polycystic Ovarian Syndrome (PCOS) and Understanding Standard of Care Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators will measure if hepatic glucose metabolism is upregulated towards de novo
      lipogenesis (DNL) via multiple intrahepatic pathways in obese girls with PCOS and hepatic
      steatosis (HS), compared to PCOS without HS and obese controls without HS. HS will be
      correlated to relative post-prandial hyperglycemia. Post-prandial hyperglycemia will be worse
      or remain unchanged in youth treated with oral contraceptives and better with metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a cross-sectional study with 4 groups of youth. A 6 hour OGTT (Oral Glucose
      Tolerance Test) with an oral U-C13 glycerol tracer will be paired with NMR isotopomer
      analysis of serum samples to describe flux through the hepatic pentose phosphate pathway, TCA
      cycle and DNL pathways in girls with PCOS receiving lifestyle only, metformin or oral
      contraceptive treatment, and obese girls with regular menses receiving lifestyle therapy.
      Hepatic steatosis will be measured with MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hepatic fat fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Amount of fat in the liver</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hepatic metabolism ratios</measure>
    <time_frame>12 months</time_frame>
    <description>Ratio of pentose phosphate pathway, TCA cycle and fatty acid synthesis metabolites following an OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin sensitivity</measure>
    <time_frame>1 month</time_frame>
    <description>Matsuda model of IS from 6 hours OGTT data.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Obesity</condition>
  <condition>Hepatic Steatosis</condition>
  <arm_group>
    <arm_group_label>Untreated PCOS</arm_group_label>
    <description>PCOS per NIH criteria. Obese Lifestyle treatment only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin PCOS</arm_group_label>
    <description>PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Contraceptive PCOS</arm_group_label>
    <description>PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Control group</arm_group_label>
    <description>Obese Regular menses at least 18 months post-menarche Females only</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>oral glucose tolerance test</intervention_name>
    <description>6 hours OGTT</description>
    <arm_group_label>Untreated PCOS</arm_group_label>
    <arm_group_label>Metformin PCOS</arm_group_label>
    <arm_group_label>Oral Contraceptive PCOS</arm_group_label>
    <arm_group_label>Obese Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI of liver</intervention_name>
    <description>MRI of the liver and use of DIXON method</description>
    <arm_group_label>Untreated PCOS</arm_group_label>
    <arm_group_label>Metformin PCOS</arm_group_label>
    <arm_group_label>Oral Contraceptive PCOS</arm_group_label>
    <arm_group_label>Obese Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA for hepatic steatosis related genes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Girls age 12-21. Obese &gt;90th percentile for BMI for age.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female

          2. Ages 12-21

          3. Sedentary- less than 2.5 hours of moderate (jogging, swimming etc) exercise a week.

          4. BMI equal or greater than the 90th percentile for age and gender

          5. For PCOS groups:

               -  (NIH definition) irregular menstrual cycles at least 1.5 years after menarche,
                  and

               -  either clinical evidence of hyperandogenism, or

               -  elevated Testosterone (above the norms for age/tanner stage) at time of
                  screening, or documented prior to initiation of therapy for OCP and metformin
                  groups.

          6. For PCOS groups:

               -  patients un-treated or currently treated with either Metformin 1500-2000 mg a
                  day, or

               -  oral contraception (30-35 mcg ethynyl estradiol a day) for at least 6 months,
                  with &gt; 80% adherence confirmed via refill frequency from pharmacy.

          7. For non-PCOS groups:

               -  regular menstrual cycles at least 1.5 years after menarche, and

               -  no clinical evidence of hyperandrogenism.

        Exclusion Criteria:

          1. Use of medications known to affect insulin sensitivity:

               -  oral glucocorticoids within 10 days,

               -  atypical antipsychotics,

               -  immunosuppressant agents,

               -  HIV medications.

               -  Nexplanon, Depo-Provera or Mirena progesterone only contraceptives.

               -  Dermal patch or vaginal ring contraception methods.

               -  For controls only: metformin or oral contraception.

          2. Currently pregnant or breastfeeding women. Development of pregnancy during the study
             period will necessitate withdrawal from the study.

          3. Severe illness requiring hospitalization within 60 days

          4. Diabetes, defined as Hemoglobin A1C &gt; 6.4%

          5. BMI percentile less than the 90th percentile for age and sex.

          6. Weight &gt;325 lbs or &lt;84 lbs.

          7. Anemia, defined as Hemoglobin &lt; 10 mg/dL

          8. Diagnosed major psychiatric or developmental disorder limiting informed consent

          9. Implanted metal devices that are not compatible with MRI

         10. Use of blood pressure medications

         11. Known liver disease other than NAFLD or AST or ALT &gt;150 mg/mL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females only</gender_description>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie C Green, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie C Green, MD, PhD</last_name>
    <phone>303/953-2328</phone>
    <email>melanie.green@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anshutz Medical Campus/Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesenia Garcia</last_name>
      <phone>720-777-6984</phone>
      <email>yesenia.garciareyes@childrenscolorado.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic de novo lipogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

